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Abstract: Interleukin-1 receptor-associated kinases (IRAKs) are key components in the signal transduction pathways 
utilized by interleukin-1 receptor (IL-1R), interleukin-18 receptor (IL-18R), and Toll-like receptors (TLRs). Out of four 
members in the mammalian IRAK family, IRAK-4 is considered to be the “master IRAK”, the only family member 
indispensable for IL-1R/TLR signaling. In humans, mutations resulting in IRAK-4 deficiency have been linked to 
susceptibility to bacterial infections, especially recurrent pyogenic bacterial infections. Furthermore, knock-in 
experiments by several groups have clearly demonstrated that IRAK-4 requires its kinase activity for its function. Given 
the critical role of IRAK-4 in inflammatory processes, modulation of IRAK-4 kinase activity presents an attractive 
therapeutic approach for the treatment of immune and inflammatory diseases. The recent success in the determination of 
the 3-dimensional structure of the IRAK-4 kinase domain in complex with inhibitors has facilitated the understanding of 
the mechanistic role of IRAK-4 in immunity and inflammation as well as the development of specific IRAK-4 kinase 
inhibitors. In this article, we review the biological function of IRAK-4, the structural characteristics of the kinase domain, 
and the development of small molecule inhibitors targeting the kinase activity. We also review the key pharmacophores 
required for several classes of inhibitors as well as important features for optimal protein/inhibitor interactions. Lastly, we
summarize how these insights can be translated into strategies to develop potent IRAK-4 inhibitors with desired properties 
as new anti-inflammatory therapeutic agents. 
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INTRODUCTION AND BIOLOGY 
  Chronic inflammatory disorders and autoimmune 
diseases are critical health problems that require therapeutic 
interventions and affect the lives of millions of people 
worldwide. In addition, at least some components of other 
common diseases, for example, type 2 diabetes and cardio-
vascular diseases, are associated with deregulation of 
inflammatory signals. Understanding the intricately regu-
lated nature of inflammatory modulation and the complex 
signaling systems involved is the key to devising potential 
therapeutic strategies. As multiple cytokines, mediators, and 
signaling pathways are involved in various inflammatory 
disorders, one of the main challenges is to identify key 
target(s) that impact the most relevant pathways.  
  Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4) 
[1] is an essential signal transducer downstream of inter-
leukin-1 receptor (IL-1R), interleukin-18 receptor (IL-18R), 
and Toll-like receptors (TLRs). All these receptors contain a 
conserved intracellular Toll and interleukin-1 receptor (TIR) 
domain [2]. TLRs receive signals from ligands that are 
mainly derived from or in reaction to different micro-
organisms or endogenous stimuli and initiate the first-wave 
of inflammatory signals and innate immune responses [3, 4]. 
Therefore, TLRs play a key role in many disease processes, 
including response to infections and various auto-inflam-
matory disorders, and are implicated in many other human  
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diseases [5]. IL-1, like tumor necrosis factor- (TNF-) and 
other major cytokines, is a key contributor to the inflam-
mation network that propagates and amplifies signals. 
Furthermore, signaling pathways mediated by TLRs, IL-1R, 
and other cytokine receptors may communicate in various 
cross-talk mechanisms. Therefore, a key signaling molecule 
downstream of IL-1R and TLRs would have profound 
effects on overall inflammatory responses and may be an 
effective therapeutic target for various diseases associated 
with deregulated inflammation. 
  Three lines of evidence suggest that the presence of 
IRAK-4 is absolutely required for TIR signaling. Firstly, in 
MyD88-dependent TIR signaling, IRAK-4 is the initial 
receptor-proximal protein kinase that is recruited and 
activated upon ligation of receptors, and it interacts with 
multiple, key downstream signaling molecules [1]. Secondly, 
targeted deletion of IRAK-4 in mice revealed severe defects 
in cytokine responses and downstream signaling pathways 
induced by IL-1R and TLRs [6]. Thirdly, human patients 
who are deficient in IRAK-4 due to gene deletion/mutations 
have been described [7]. Cells derived from these patients 
clearly exhibit impaired responses to IL-1, IL-18, or 
exogenous MyD88-dependent TLR ligands [7]. Together 
with its broad impact on TLR and IL-1R signaling, the 
evidence collectively suggests that IRAK-4 may be a key 
target for therapeutic intervention in various inflammatory 
disorders. 
  One obvious question that follows is whether inhibition 
of IRAK-4 may cause too broad an impact, rendering the 
side effects intolerable, given the molecule’s central position IRAK-4 Inhibitors for Inflammation  Current Topics in Medicinal Chemistry, 2009, Vol. 9, No. 8     725
in multiple signaling pathways. Children with IRAK-4 
deficiency are indeed susceptible to certain pyogenic 
infections, particularly Streptococcus, but no severe viral or 
parasitic infections have been reported [7, 8]. Despite the 
critical role that IRAK-4 plays in TIR signaling, adult 
patients with the deficiency are not prone to chronic infec-
tions. In fact, as these patients approach adolescence, suscep-
tibility to infections becomes increasingly rare [9, 10]. It is 
possible that modulation of IRAK-4 function through kinase 
inhibition, for example, may provide therapeutic benefits by 
toning down inflammatory responses, while protective 
immunity remains sufficiently preserved to protect against 
microbial infections. 
  IRAK-4 belongs to a family of mammalian IRAKs that 
include IRAK-1 [11], IRAK-2 [12], and IRAK-M, also 
known as IRAK-3 [13]. All four IRAK family members 
appear to play a role in Toll and IL-1R signaling [14-16]. 
They share a similar domain structure containing a con-
served N-terminal death domain (DD) and a central kinase 
domain (KD). Upon stimulation of IL-1R, IL-18R, and most 
TLRs, MyD88 is the first adaptor protein which binds to the 
receptors and is followed by recruitment of IRAK-4 and 
activation of its kinase activity (Fig. 1). IRAK-4 transduces 
inflammatory signals by rapidly activating IRAK-1. This is 
followed by the activation of IRAK-2, which has recently 
been shown to play a key role in sustaining pro-inflam-
matory cytokine production [17]. Signals are then relayed to 
the TRAF6 protein complex, facilitating downstream 
signaling events. IRAK-M appears to play a negative 
regulatory role in this process [18]. Mouse knock-out studies 
have demonstrated an essential role for IRAK-4 in IL-1R, 
IL-18R, and most TLR signaling [6], while IRAK-1-
deficient mice and cells show partial defects or defects in 
more specific pathways [19-21]. Further supporting its 
essential function, IRAK-4 shares the highest homology with 
the  Drosophila Pelle protein, an ortholog of mammalian 
IRAKs. Pelle plays a critical role in the Drosophila Toll 
signaling pathway and requires its kinase activity for signal 
transduction [22]. 
  IRAK-4 knock-out mice are severely impaired in 
signaling and cellular responses to IL-1, IL-18, and most 
TLR ligands. IRAK-4-mediated signals are essential for 
downstream activation of JNK, NF-B, and p38 MAPK [6, 
23], all of which play a role in cytokine and inflammatory 
responses. However, it is worth noting that certain TLRs also 
mediate signals to activate the IRF family of transcription 
factors that lead to induction of additional genes, including 
type I interferons [4, 24]. Different TLRs may recruit distinct 
MyD88 family members of adaptors and activate different 
IRFs [4]. Among these, IRAK-4 appears to only play a role 
in the activation of IRF5 and IRF7 mediated through TLR7 
and TLR9 [25-27] but not in other pathways leading to IRF 
and type I interferon responses. Studies with IRAK-4-
deficient patients have demonstrated reduced interferon-
(IFN-) and IFN- production in response to TLR ligands 
while responses to herpes simplex virus (HSV) and vesicular 
Fig. (1). TIR signaling pathways. This figure illustrates that inhibition of IRAK-4 kinase activity should primarily block MyD88-dependent 
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stomatitis virus (VSV) remained intact [28]. The involve-
ment of IRAK-4 in TLR7 and TLR9 signaling, coupled with 
the observation that dual inhibition of TLR7 and TLR9 in 
lupus-prone mice results in amelioration of disease symp-
toms, indicates that IRAK-4 may be a suitable therapeutic 
target for systemic lupus erythematosus (SLE) [26, 29]. 
  IRAK-4 may transduce signals through physical protein-
protein interaction and through its kinase activity, which 
activates downstream molecules such as IRAK-1 [1]. It is 
therefore critical to examine if IRAK-4 kinase activity is 
essential for its signaling functions. Initial studies using 
biochemical approaches, over-expression experiments, and 
reconstitution of IRAK-4 knock-out cells with kinase 
inactive mutants all point to the requirement of IRAK-4 
kinase activity for its signal transduction [1, 30]. At a 
minimum, specific pathways such as IL-1-induced NF-B
and JNK that were examined in these systems required 
IRAK-4 kinase functions. However, cells expressing only an 
IRAK-4 kinase inactive mutant were still able to respond to 
IL-1 in NF-B activation and cytokine production, although 
the response was greatly reduced compared to wild type 
[30]. Another study utilizing IRAK-4 mutant variants 
identified from human patients demonstrated that IRAK-4 
with a truncated kinase domain inhibited IL-1 signaling by 
disrupting formation of the receptor complex [8].  
  Several recent publications using different strains of 
IRAK-4 kinase-dead mutant knock-in mice further confirm 
the importance of IRAK-4 kinase activity [23, 31-34]. In 
essence these knock-in mice and cells derived from these 
mice express only IRAK-4 kinase inactive mutant, a 
mutation of the conserved residues in the ATP binding 
pocket, and no wild type IRAK-4. While there are some 
variations of the experiments and findings among different 
knock-in strains, these mutants collectively demonstrate 
substantial defects in signaling pathways and cytokine induc-
tion in response to IL-1 and various TLR ligands. These 
signaling and cytokine defects observed in knock-in mutants 
appear similar to those observed in IRAK-4 knock-out mice 
[23, 33, 34].  
  All of these data suggest that IRAK-4 may be a suitable 
target for inflammatory diseases involving multiple receptors 
including IL-1R (rheumatoid arthritis (RA) and osteoarthritis 
(OA) [35]), IL-18R (inflammatory bowel disease (IBD) [36, 
37]), TLR2, 4 (RA [38]), and TLR7, 9 (SLE [26, 29]).  
STRUCTURAL FEATURES OF THE IRAK-4 KINASE 
DOMAIN  
  The recent success in the determination of the three 
dimensional structures of the IRAK-4 kinase domain by X-
ray crystallography has provided great insights into IRAK-
4’s mechanistic role in immunity and inflammation, its 
inhibitor binding, and the design of selective inhibitors as 
potential therapeutics. To date, six crystal structures of the 
IRAK-4 kinase domain have been deposited with the RCSB 
Protein Data Bank (PDB) (Table 1); two of them are solved 
in the apo form, one in complex with a non-hydrolysable 
ATP analogue AMP-PNP, two in complex with the generic 
kinase inhibitor staurosporine, and one in complex with a 
synthetic inhibitor derived from a medicinal chemistry effort 
[39, 40]. 
  The overall structure of the IRAK-4 kinase domain 
adopts a canonical fold of classical protein kinases, with the 
ATP-binding cleft sandwiched between a bilobal 
arrangement (Fig. 2). The N-terminal lobe (N-lobe) consists 
mainly of a twisted five-stranded antiparallel -sheet and one 
 helix (C), and the larger C-terminal lobe (C-lobe) is 
predominantly -helical. Structural comparison of IRAK-4 
kinase with other serine/threonine or tyrosine kinases shows 
that most of the conserved core structural elements are in 
good alignment. Yet, the structure reveals a few unique 
features for IRAK-4 kinase, including an additional  helix 
from the N-terminal extension in the N-lobe, a longer loop 
between helices D and E (residues 276-282, loop DE), 
and a significantly moved helix G (residues 395-406) as 
well as its adjoining loops (residues 383-394 and 407-423). 
N-Terminal Extension  
  The IRAK-4 protein kinase constructs that yielded crystal 
structures have extra ordered residues extending from the 
normal N-terminus of the kinase domain. This N-terminal 
extension was found to be important for protein expression 
as well as kinase activity when compared with the full length 
protein [39]. Many other protein kinase structures also reveal 
such N-terminal extensions. While these extensions share no 
sequence homology or structural similarity, they have the 
common characteristic of packing tightly against the -sheet 
and becoming an integral part of the overall fold [41]. In the 
case of IRAK-4, the N-terminal extension forms a short extra  
Table 1. Structures of Human IRAK-4 Kinase Domain Deposited at the RCSB Protein Data Bank 
PDB code  Ligand  Resolution (Å)  Phosphorylation Site  Refs 
2O8Y  None (Apo)  2.4  pT342, pT345   
2OIB  None (Apo)  2.0  pT342, pT345, pS346  [40] 
2OID  AMP-PNP  2.3  pT342, pT345, pS346  [40] 
2OIC  Staurosporine  2.4  pT342, pT345, pS346  [40] 
2NRY Staurosporine  2.2  pT345  [39] 
2NRU Benzimidazole  2.0  pT345,  pS346  [39] IRAK-4 Inhibitors for Inflammation  Current Topics in Medicinal Chemistry, 2009, Vol. 9, No. 8     727
Fig. (2). Overall structure of the IRAK-4 kinase domain (PDB 
code: 2NRU). 
-strand packed in parallel with the 4 strand, an extra -
helix (B), and then a loop. The helix (B) crosses over the 
five-stranded -sheet of the N-lobe and makes hydrophobic 
interactions with the concave hydrophobic surface of the -
sheet. The following loop region is described as having three 
helix-capping motifs [40], including an ST motif (residues 
177-181) [42], an ASX motif (residues 181-183) [43], and a 
solvent-exposed Schellman motif (residues 184-189) [44] 
characterized by hydrogen bonding interactions between the 
backbone amines of Gly188/Gly189 and the backbone 
carbonyls of Pro184/Ile185. 
  Interestingly, while the Schellman loop points down to 
the C-lobe into the cleft region between the two lobes, the 
loop DE sticks out of the C-lobe and points up to the N-
lobe in the cleft region as well. Together, the Schellman loop 
and the extra long loop DE provide an extended protein 
surface area for the ATP binding site in IRAK-4 (Fig. 3a). 
Activation Loop 
  Regulation of IRAK-4 kinase activity has been reported 
by the autophosphorylation of three sites in the activation 
loop, i.e., Thr342, Thr345, and Ser346 [45]. All the reported 
IRAK-4 kinase domain structures are solved in the phos-
phorylated forms, although the phosphorylation states vary 
among them (Table 1). The conformation of the phos-
phorylated activation loop of IRAK-4 is, in general, similar 
to that of other phosphorylated serine/threonine kinases such 
as cAPK [46], cyclin-dependent kinase CDK2 [47], and 
MAP kinase ERK2 [48] as well as tyrosine kinases such as 
LCK [49] and insulin receptor kinase (IRK) [50]. pSer346 
points outward to the solvent and its phosphate group makes 
no contacts with protein. pThr342 is positioned away from 
the catalytic site with its phosphate moiety coordinated by 
the side chains of Lys367 of helix F and Lys441 of helix 
EF. pThr345 is folded back towards the catalytic center in 
the protein core with its phosphate group positioned to 
compensate for a positively charged pocket formed by three 
arginine residues, i.e., Arg310 that precedes the catalytic 
base Asp311 in the catalytic loop, Arg334 that is the third 
residue following the signature DFG motif upstream of the 
activation loop, and Arg347, which is also in the activation 
loop but is downstream of the two phosphorylated residues. 
The phosphate group of pThr345 is coordinated directly to 
Arg334 (Fig. 3b). Additional interactions with the phosphate 
group of pThr345 are a water-mediated hydrogen bond with 
Arg310 of the catalytic loop and a direct hydrogen bond to 
the backbone amide nitrogen of Ser346. Here, the structures 
suggest that pThr345 is the prototypical phosphoresidue 
responsible for the activation of IRAK-4 kinase. The 
phosphorylations of Thr342 and Ser346 might play roles in 
stabilization of the activation loop in the active state. 
  Interestingly, the phosphate interaction pattern of IRAK-
4 kinase differs from that of other phosphorylated serine/ 
threonine protein kinases, where two or three phosphate-
binding residues are normally observed [46, 48, 51]. Among 
these positively charged residues, the ones from the catalytic 
loop and helix C are believed to be important for promoting 
the correct orientation and electrostatic environment for the 
catalytic base Asp311 as well as the proper active orientation 
for helix C [52]. Instead, the pattern of the phosphate 
ligand binding interactions of IRAK-4 resembles closely 
those of tyrosine protein kinases, such as LCK [49], IRK 
[50], insulin-like growth factor 1 receptor kinase (IGF1RK) 
[53], and more recently Janus Kinase 3 (JAK3) [54]. All of 
these kinases share a common motif for the phosphate ligand 
binding interaction, i.e. with a single primary phosphate 
ligand arginine or lysine in the activation loop, in an equi-
valent position to Arg334 of IRAK-4. In fact, the phosphate 
interaction pattern of IRAK-4 is almost identical to that of 
protein tyrosine kinase IRK, although IRAK-4 is a 
serine/threonine protein kinase.  
Substrate-Binding Site 
  In comparison with other protein kinases, IRAK-4 kinase 
also presents a unique substrate-binding site. The fold of the 
P+1 pocket of IRAK-4, defined by the downstream surface 
loop of the activation loop to helix EF (residues 
I
348VGTTAYM
355), closely resembles those in cAPK and 
PhK, with a serine/threonine kinase conserved threonine 
residue Thr351 (corresponding to Thr186 in PhK) interacting 
with catalytic base Asp311 and Lys313 from the catalytic 
loop (Fig. 3c). Yet, there is a substantial difference in the 
nature and size of the binding site in IRAK-4. Instead of 
being lined with all hydrophobic residues in the P+1 pocket, 
such as Val183, Pro187, and Leu190 in PhK, and Leu198, 
Pro202, and Leu205 in cAPK, IRAK-4 has Ile348, Thr352, 
and Met355. As a result, IRAK-4 substrates are likely to 
adopt a similar conformation around the P+1 site, but with 
different specificity. A large and more polar P+1 residue is 
preferred to interact with Thr352 in the P+1 loop. Moreover, 
two charged residues, Arg347 from the activation loop and 
Asp220 from the loop following helix C, reach the P+2 728 Current Topics in Medicinal Chemistry, 2009, Vol. 9, No. 8 Wang et al. 
site. Thus, a polar or charged P+2 residue is preferred for the 
IRAK-4 substrate.  
  The IRAK-4 structure presents a distinctive change in the 
region of helix G which moves significantly away from the 
active site and helix EF, with about a 10 Å shift as 
compared with other protein kinases such as tyrosine kinase 
LCK[49, 55] and serine/threonine kinase cAPK [46]. Such a 
dramatic movement of the helix G and its flanking loops 
has a direct impact on the substrate-binding site of IRAK-4. 
The shift made by helix G in IRAK-4 offers an open space 
at the side of the P+1 pocket and creates a large hydrophobic 
groove bound by the region of the C-terminal activation 
loop, the P+1 loop, and helix G (Fig. 3d). Interestingly, this 
hydrophobic groove is typically the location for helix G of 
other protein kinases. While helix G shifts away from the 
P+1 site, the loop preceding helix G actually shifts closer to 
the P+1 loop with Val387 making van der Waals contact 
with Ala353 in the P+1 loop (Fig. 3c). In comparison with 
PhK, where the P-2 residue from substrate peptide approa-
ched this region, a large hydrophobic residue is likely 
preferred at P-2 for the IRAK-4 substrate. 
ATP-Binding Site and Tyrosine Gatekeeper 
  The ATP-binding site between the two lobes of protein 
kinases has been the target for small molecule inhibitors to 
modulate kinase activities. Elucidation of unique 
characteristics in the ATP-pocket of each individual kinase 
becomes a must for successfully designing potent and 
selective inhibitors. While IRAK-4 shows a similar overall 
core structure for the ATP binding site compared with other 
protein kinases, a pivotal residue at the center of the ATP-
binding site, commonly known as a “gatekeeper”, is unique 
for IRAK-4. The term “gatekeeper” refers to a residue 
upstream of the hinge loop that connects the two lobes. The 
gatekeeper residue controls access to a pre-existing internal 
 a.  b. 
 c.  d. 
Fig. (3). Unique features of the IRAK-4 kinase domain. a) The Schellman loop in the N-terminal extension (shown in magenta) and the extra 
long loop DE (shown in orange) extends the ATP-binding pocket (PDB code: 2NRU). b) Activation loop of IRAK-4 with its phosphate 
ligand binding interactions resembling that of protein tyrosine kinases (PDB code: 2OIB). c) The P+1 site of IRAK-4 with a conserved 
threonine residue in serine/threonine kinases, Thr315, interacting with the catalytic base Asp311 and Lys313 (PDB code: 2NRU). d) The 
substrate-binding area of IRAK-4, docked with a putative substrate peptide from the activation loop of IRAK-1 (shown in yellow sticks). IRAK-4 Inhibitors for Inflammation  Current Topics in Medicinal Chemistry, 2009, Vol. 9, No. 8     729
hydrophobic pocket at the back of the ATP-binding site that 
nucleotides do not exploit [56]. While nearly 20% of kinases 
in the human kinome possess a smaller threonine residue as a 
gatekeeper, 40% of them have a large methionine residue, 
and almost 15% of them have a large phenylalanine residue. 
IRAK-4 has a tyrosine residue, Tyr262, at this position. A 
tyrosine gatekeeper seems to be exclusive to the IRAK 
family of kinases when compared with a limited set of more 
than 400 kinases in the human kinome database. IRAK-1, 
IRAK-2, and IRAK-M also have a tyrosine as the gatekeeper 
residue. 
  The gatekeeper residue has been shown to play a critical 
role in controlling kinase selectivity for various small 
molecule ATP-competitive inhibitors. The back hydrophobic 
pocket is more readily probed by a diverse class of inhibitors 
for protein kinases with a smaller gatekeeper residue like 
threonine. A bulkier gatekeeper, such as methionine or 
phenylalanine, seen for the majority of protein kinases, 
makes the entrance to this pocket relatively narrow. Here, 
with tyrosine at the gatekeeper position and its hydroxyl 
group forming a direct hydrogen bond interaction with one 
of the carboxylate oxygen atoms of the conserved glutamate 
Glu233 from helix C (Fig. 4a), the back hydrophobic 
pocket of the ATP binding site is completely blocked for 
access in IRAK-4 (Fig. 4b). 
  In the apo crystal structure of IRAK-4 reported by 
Kuglstatter  et al. (PDB code: 2OIB) [40], two distinct 
protein conformations are observed in the four independent 
protein molecules in the crystallographic asymmetric unit. 
The two conformations vary mainly in their relative 
orientation between the N- and C-lobes, with helix C, the 
Gly-rich loop, and the N-terminal extension experiencing the 
most evident movements (Figs. 5a, b). These two confor-
mations are referred to as “helix C-in” and “helix C-out” 
[40]. 
  Conformational changes in helix C have been described 
as one of the signature features of the kinase activation 
mechanism for both serine/threonine and tyrosine kinases 
[57]. Upon kinase activation, as a coupled action of the 
activation loop phosphorylation, helix C undergoes a 
conformational change by moving into the catalytic center 
and facilitating the salt bridge between the invariant catalytic 
lysine residue and the conserved glutamate residue on helix 
C. Hence, “helix C-in and C-out” conformations are 
normally associated with kinase activity states, with “helix 
C-in” and the lysine-glutamate salt-bridge representing the 
active form of kinases. In IRAK-4, tyrosine gatekeeper 
Tyr262, which acts as a principal partner for the invariant 
glutamate Glu233 of helix C, interferes with this classical 
ion-pair interaction. In both observed conformations of 
IRAK-4, the gatekeeper Tyr262 forms direct hydrogen bond 
interactions with Glu233 (Fig. 5c). Interestingly, the lysine 
glutamate salt bridge is observed only in the “helix C-out” 
conformation for IRAK-4 (Fig. 5d). Here, the glutamate 
Glu233 forms hydrogen bond interactions with both the 
catalytic Lys213 and the gatekeeper Tyr262. 
  The different protein conformations are also observed in 
other solved IRAK-4 structures. However, only one confor-
mation was usually observed for each of the structures. In 
the other deposited apo structure (PDB code: 2O8Y), both 
independent protein molecules were crystallized in the “helix 
C-in” conformation. In the cocrystal structure with AMP-
PNP (PDB code: 2OID), the protein molecules mainly 
assume the “helix C-in” conformation. While the protein 
molecules adopt primarily the “helix C-out” conformation 
in the staurosporine cocrystal structures (PDB code: 2NRY 
and 2OIC), all four independent protein molecules take up 
the “helix C-in” conformation in the IRAK-4 cocrystal 
structure with a benzimidazole synthetic inhibitor (PDB 
code: 2NRU). Apparently, both protein conformations 
coexist in solution [40]. Since the “helix C-in” confor-
mation is associated with the AMP-PNP bound form, this 
form was proposed to represent the active form of the kinase 
[40]. 
In summary, the structural data revealed that IRAK-4, 
although characterized as a serine/threonine kinase, contains 
Fig. (4). The gatekeeper region and the ATP-binding pocket of IRAK-4. a) The unique Tyr262 gatekeeper interacts with an absolutely 
conserved glutamate residue Glu233, disrupting the usual Glu-Lys salt bridge (PDB code: 2OIB). b) The ATP-binding site has no back 
pocket due to the tyrosine gatekeeper (PDB: 2OID). 730 Current Topics in Medicinal Chemistry, 2009, Vol. 9, No. 8 Wang et al. 
characteristic structural features of both serine/threonine and 
tyrosine kinases, suggesting the possibility that IRAK-4 is a 
dual specificity kinase. This finding provides valuable 
insight into a better understanding of the role of IRAK-4 in 
both innate and acquired immunity. In addition, IRAK-4 
offers a few unique features when compared with other 
protein kinases, especially the tyrosine gatekeeper and the 
extended ATP binding area, which have a direct impact on 
inhibitor design. 
IRAK-4 INHIBITOR DEVELOPMENT 
Potent and selective small molecule inhibitors targeting 
IRAK-4 kinase activity are currently being pursued as 
potential therapeutics for autoimmune and inflammatory 
diseases [39, 58-64]. A few novel series of potent IRAK-4 
kinase inhibitors have been described, including amino-
benzimidazoles [59], thiazole or pyridine amides [60], 
imidazo[1,2-a]pyridines [61, 62], imidazo[1,2-b]pyridazines, 
and benzimidazole-indazoles [58, 64]. The chemical 
structures of some representative inhibitors from these series 
are shown in Fig. 6.
Aminobenzimidazole Inhibitors 
  A series of novel acyl-2-aminobenzimidazole inhibitors 
(7 and 8 in Fig. 7) were discovered as a result of high-
throughput screening of a small molecule library against 
IRAK-4 kinase [59]. Comprehensive SAR studies carried out 
by Powers et al. resulted in significant improvement of 
potency as well as determination of the key structural 
features of the series. 
  The central amide functionality was found to be critical 
for IRAK-4 inhibition, since either removal of the amide 
carbonyl or replacement of the amide moiety with urea and 
sulfonamide groups resulted in a substantial reduction of 
IRAK-4 inhibition, as did the replacement of the free amide 
N-H with N-alkyl substitution. Modification of the benza-
mide aryl ring with a limited set of substituents showed that  
 a.  b. 
 c.  d. 
Fig. (5). The dual conformations of apo IRAK-4 (PDB code: 2OIB). a) Overall two conformations of IRAK-4. b) Two conformations differ 
mainly in the N-lobe where helix C, the Gly-rich loop, and the N-terminal extension show evident movements. c) Two conformations are 
symbolized by “helix C-in” and “helix C-out” positions, where the invariant Glu233 shows different side chain conformations. d) The 
usual Glu-Lys salt bridge is observed only in the “helix C-out” conformation. IRAK-4 Inhibitors for Inflammation  Current Topics in Medicinal Chemistry, 2009, Vol. 9, No. 8     731
Fig. (7). Initial IRAK-4 inhibitor hits from an aminobenzimidazole 
series. 
some changes were allowed, but a 3-nitro group seemed to 
result in the highest potency. SAR around the benzimidazole 
group was explored on the 4-, 5-, 6-, and 7-positions, and the 
N was substituted with alkyl groups. An SAR study of the 
substituents on the ring demonstrated the importance of the 
benzimidazole ring. Improvements in potency were observed 
from the modifications on the 5-position and the N-alkyl 
substitutions. 
 Compound  1 (Fig. 6) represents one of several potent 
inhibitors developed from the aminobenzimidazole SAR 
exploration by Powers et al. [39]. The cocrystal structure of 
IRAK-4 with 1 (PDB code: 2NRU) revealed the inhibitor 
bound at the ATP-binding site, with the 3-nitrobenzamide 
ring positioned towards the back and the benzimidazole ring 
at the front (Fig. 8a). The binding of 1 to IRAK-4 is 
mediated through several hydrogen bonds and numerous van 
der Waals interactions. Compound 1 makes a hydrogen bond 
with the hinge region of IRAK-4 mainly through the amide 
carbonyl, which accepts a hydrogen bond from the backbone 
amide of Met265. The 3-position N of the benzimidazole 
ring also has a favourable hydrogen bond distance to the 
carbonyl moiety of Met265. The importance of the free 
amide N-H was investigated, and replacements of the amide 
N-H lost activity [59]. Together, the data suggested that the 
necessity of the free amide N-H may indicate a requirement 
for the inhibitors to be able to populate a tautomeric form via 
abstraction of this hydrogen [59]. In the back, the 3-
nitrobenzamide ring forms a - stacking interaction with 
the gatekeeper Tyr262, with the nitro moiety forming a weak 
hydrogen bond with catalytic Lys213. In the middle, the N-
Fig. (6). Chemical structures of representative IRAK-4 inhibitors discovered through medicinal chemistry efforts. 
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propanol moiety points to the ATP ribose-binding area with 
its hydroxyl group pointing to Asp272 of helix D. At the 
front, the trimethyl acetyl ester substitution at the 5-position 
of the benzimidazole ring points to the solvent-exposed 
region with its carbonyl moiety forming a hydrogen bond 
with Arg273 of helix D.  
  Comparison of the IRAK-4 complex structures with 1
(PDB: 2NRU) and AMP-PNP (PDB: 2OID) shows that 1
binds in partial overlap with the nucleotide, with its amide 
linker occupying the binding area of the adenine ring but 
extending more outward to the front of the ATP-binding area 
which ATP does not exploit (Fig. 8b). The unique extended 
front area of IRAK-4 presents an appealing opportunity for 
the design of selective inhibitors.  
Thiazole and Pyridine Amide Inhibitors 
  The thiazole amide 9 (Fig. 9) was identified as an initial 
hit from screening a small molecule library against IRAK-4 
[60]. SAR studies around 9 carried out by Buckley et al. [60] 
resulted in a set of potent compounds with excellent 
solubility and good levels of exposure in vivo.
  In the absence of cocrystal structural data, homology 
modelling and in silico docking were used to envisage the 
binding mode of 9 in IRAK-4. The thiazole amides were 
predicted to have the amide linker forming a key interaction 
to the hinge with the thiazole pyridine ring pointing towards 
the back and the substituted phenyl sitting at the front of the 
ATP-binding site. Initial SAR efforts were focused around 
the phenyl ring, for which a diverse set of commercially 
available phenyls were selected, including mono- and multi-
substituted phenyls. The most active compounds from this 
effort were those having substitution at both the ortho- and 
the para-positions, such as 2 (Fig. 6), which demonstrated 
significantly improved potency against IRAK-4 compared 
with the initial hit 9.
  To facilitate the investigation of SAR around the other 
end of the molecule, i.e, the thiazole pyridine rings, the 
thiazole ring was replaced by another pyridyl ring. 
Compound  10 (Fig.  9) showed a similar potency to its 
thiazole analogue 9. SAR around the terminal pyridine ring 
was found to be sensitive; the orientation and basicity of the 
nitrogen atom seemed important for modulating activity 
against IRAK-4. Pyrazoles showed improvement in potency 
against IRAK-4. The most active inhibitors, such as 3 (Fig. 
6), were developed by combining the most promising 
substituted phenyls from the thiazole sub-series and the best 
terminal pyridine replacement from the pyridine sub-series. 
The authors also indicated that these potent inhibitors 
showed reasonable stability in rat and human microsomes, 
exposure in Lewis rats, and aqueous solubility [60].  
Fig. (8). Inhibitor compound 1 binding in IRAK-4. a) the binding mode of 1 in the ATP-binding pocket of IRAK-4 (PDB code: 2NRU). b) 1
superimposed on the AMP-PNP complex structure of IRAK-4 (PDB code: 2OID).  
Fig. (9). Initial thiazole amide IRAK-4 inhibitor and its pyridine amide analogue. 
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Imidazo[1,2-a]pyridine Inhibitors 
  Through a kinase project cross-screening effort of 
medicinal chemistry target compounds and advanced inter-
mediates, a 2-aminopyrimidine-based imidazo[1,2-a]pyri-
dine inhibitor 11 (Table 2) from a JNK kinase project was 
identified as a potent inhibitor of IRAK-4 [62]. However, the 
aminopyrimidine-based scaffold is not novel as a kinase 
inhibitor; the aminopyrimidine moiety often forms “plug” 
(two hydrogen bonds) interactions with the hinge backbone 
of the ATP-binding site [65, 66]. To elucidate the novelty of 
this series as an IRAK-4 inhibitor, Buckley et al. performed 
in silico docking with homology modelling and surrogate 
crystal structure analysis together with preparation of some 
analogues [62]. This effort led to the identification of the 
imidazopyridine nitrogen atom N1, not the aminopyrimidine 
moiety as observed in other kinase projects, as the key 
structural feature of the series for the hinge interaction. 
 Figure  10a shows the binding mode of the N-methyl 
capped 13 (IRAK-4: IC50 = 0.4 M; JNK-3: IC50 = 3 M) in 
a closely related homologous JNK-3 crystal structure (PDB 
code: 3CGF), which is consistent with the docking results 
from the IRAK-4 homology models [62]. While the nitrogen 
N1 atom of the imidazopyridine moiety serves as a hydrogen 
bond acceptor for the hinge backbone amide, the amino-
pyrimidine sits in the ribose-binding area for ATP. A 
structurally related aminopyrimidine 14, which is a more 
potent inhibitor for JNK-3 (IC50 = 270 nM) and less potent 
for IRAK-4 (IC50 = 3 M), displayed an altered binding 
mode in a JNK-3 crystal structure (Fig. 10b) (PDB code: 
3CGO). Here the inhibitor adopted the typical binding mode 
Table 2. Inhibition of IRAK-4 by Imidazo[1,2-a]Pyridine Analogs Identified from a Cross-Screening of other Kinase Projects 
Compound X  R  IRAK-4 
IC50 (M)
JNK 
IC50 (M)
11 NH H  0.216  3.8  (JNK-1) 
12 NH  Me  0.200  33% inhib. @ 10M (JNK-1)  
13 CH2 Me  0.400  3.0  (JNK-3) 
14 H 3.0  0.27  (JNK-3) 
Fig. (10). Cocrystal structures of aminopyrimidines in JNK-3. a) A more potent IRAK-4 compound: binding mode of 13 in JNK-3 (PDB 
code: 3CGF). b) A more potent JNK-3 compound: binding mode of 14 in JNK-3 (PDB code: 3CGO). 
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often observed in other kinases, with the aminopyrimidine 
being the key pharmacophore for the hinge interactions. 
  Following the establishment of the key structural features 
for the series, Buckley et al. carried out more investigations 
of SAR around the lead compound 11 [61]. This effort 
brought forth two more lead compounds, 15 (an imidazo[1,2-
a]pyridino-pyridine) and 16 (a benzimidazole-pyridine), as 
the more preferred scaffolds for optimization (Fig. 11). The 
new lead series was developed to remove the initial amino-
pyrimidine motif and its associated potential promiscuity. 
The SAR around the new leads generated highly potent 
IRAK-4 inhibitors, such as 4, 5, and 6 (Fig. 6). While these 
compounds were reported to have good cellular TNF-
inhibition, good drug-like properties, and encouraging in
vitro DMPK profiles, some degree of off-target activity was 
still evident. As these molecules still have low molecular 
weights (300-350 Da), the series remains an interesting class 
for further optimization and development into potent and 
selective inhibitors.  
Imidazo[1,2-b]pyridazine and Indazole Inhibitors 
 Imidazo[1,2-b]pyridazines and indazoles were disclosed 
in two recent patents published by Biogen Idec as IRAK-4 
modulators for treatment of some inflammatory, cell proli-
Fig. (11). Lead compounds of the imidazo[1,2-a]pyridino-pyridine and benzimidazole pyridine series.
Fig. (12). Imidazo[1,2-b]pyridazine and indazole IRAK-4 inhibitors.
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ferative, and immune-related disorders [58, 64]. Apparently, 
various compounds were developed around the two key 
formulas,  17 and 20 (Fig. 12). These compounds were 
reported to exhibit IC50 values of less than 20 M, and some 
had IC50 values of less than 10 nM. However, specific IC50
values for these compounds are not shown in the patents.  
  In summary, several novel scaffolds suitable for the 
development of IRAK-4 inhibitors have been identified. 
They potently inhibit IRAK-4 kinase activity and have 
reasonable cellular potency and physicochemical properties. 
Structural analysis suggests that there are plentiful oppor-
tunities for further improvement of potency, selectivity, and 
other physicochemical properties. Further optimization of 
these promising compounds may lead to new therapeutic 
agents for inflammatory diseases.  
CONCLUSION 
  IRAK-4 is a critical molecule mediating signals in both 
innate and adaptive immune responses. Though charac-
terized functionally as a serine/threonine kinase, the crystal 
structures revealed that IRAK-4 contains characteristic 
structural features of both serine/threonine and tyrosine 
kinases, as well as additional novel attributes, including the 
unique tyrosine gatekeeper residue. The ATP-binding site in 
IRAK-4 has no deep pocket in the back but has a featured 
front pocket. This uniquely shaped binding pocket provides 
an excellent opportunity for designing IRAK-4 inhibitors 
which confer high selectivity.  
  The development of IRAK-4 kinase inhibitors has 
generated several novel classes of potent binders in the ATP-
binding pocket. Apparently, all of them are still in the early 
preclinical stage. The potential for clinical utility of IRAK-4 
inhibitors in inflammation continues to change as the role of 
IRAK-4 in the complex signaling cascade is further 
elucidated. As an example, early studies suggest that the 
IRAK-1 kinase activity might be a negative feedback signal 
[67], and it therefore seems desirable to avoid any IRAK-1 
activity in IRAK-4 compounds. However, another study 
communicated by Roche [63] suggested that pharmacologic 
inhibition of both IRAK-4 and IRAK-1 might be necessary 
to block pro-inflammatory cytokine production. The com-
pounds they described and their derivatives will hopefully 
lead to a conclusive elucidation of the relative contribution 
and the interdependencies of IRAK molecules in TIR 
signaling and inflammatory processes. 
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